Last update Aug. 19, 2022
Very Low Risk
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Nitrendipine in other languages or writings:
Nitrendipine belongs to this group or family:
Main tradenames from several countries containing Nitrendipine in its composition:
|Oral Bioavail.||10 - 30||%|
|VD||5 - 9||l/Kg|
|Tmax||1 - 3||hours|
|T½||10 - 22||hours|
|M/P ratio||0.2 - 0.5||-|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
It is a dihydropyridine-type calcium channel blocker with actions similar to those of nifedipine. It is used in the treatment of hypertension. Oral administration once or twice a day.
It is excreted into breast milk in clinically non-significant amount (White 1989), possibly due to its high percentage of binding to plasmatic proteins and very wide volume of distribution.
Evidence on other antihypertensive drugs of the same family with similar structure, pharmacokinetics and action profile (nifedipine, nimodipine, nicardipine) has shown that they are excreted into milk in non-significant amount.
Until more extensive published data about this drug regarding breastfeeding are available a safer alternative drug should be used, especially during the neonatal period and/or in case of premature infants.